当前位置: X-MOL 学术Blood › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Blood ( IF 21.0 ) Pub Date : 2022-04-21 , DOI: 10.1182/blood.2021014506
Matthew R Wilson 1 , Toby A Eyre 2 , Amy A Kirkwood 3 , Nicole Wong Doo 4 , Carole Soussain 5 , Sylvain Choquet 6 , Nicolás Martinez-Calle 7 , Gavin Preston 8 , Matthew Ahearne 9 , Elisabeth Schorb 10 , Marie-Pierre Moles-Moreau 11 , Matthew Ku 12 , Chiara Rusconi 13 , Jahanzaib Khwaja 14 , Mayur Narkhede 15 , Katharine L Lewis 16 , Teresa Calimeri 17 , Eric Durot 18 , Loïc Renaud 19 , Andreas Kiesbye Øvlisen 20 , Graham McIlroy 21 , Timothy J Ebsworth 22 , Johnathan Elliot 23 , Anna Santarsieri 24 , Laure Ricard 25 , Nimish Shah 26 , Qin Liu 27 , Adam S Zayac 28 , Francesco Vassallo 29 , Laure Lebras 30 , Louise Roulin 31 , Naelle Lombion 32 , Kate Manos 33 , Ruben Fernandez 34 , Nada Hamad 35 , Alberto Lopez-Garcia 36 , Deirdre O'Mahony 37 , Praveen Gounder 4 , Nathalie Forgeard 6 , Charlotte Lees 2 , Kossi Agbetiafa 5 , Tim Strüßmann 10 , Thura Win Htut 8 , Aline Clavert 11 , Hamish Scott 12 , Anna Guidetti 13 , Brett R Barlow 15 , Emmanuelle Tchernonog 38 , Jeffery Smith 39 , Fiona Miall 9 , Christopher P Fox 7 , Chan Y Cheah 16 , Tarec Christoffer El Galaly 20 , Andrés J M Ferreri 17 , Kate Cwynarski 14 , Pamela McKay 1
Affiliation  

Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We conducted a retrospective, international analysis of 1384 patients receiving HD-MTX CNS prophylaxis either intercalated (i-HD-MTX) (n = 749) or at the end (n = 635) of R-CHOP/R-CHOP-like therapy (EOT). There were 78 CNS relapses (3-year rate 5.7%), with no difference between i-HD-MTX and EOT: 5.7% vs 5.8%, P = .98; 3-year difference: 0.04% (-2.0% to 3.1%). Conclusions were unchanged on adjusting for baseline prognostic factors or on 6-month landmark analysis (n = 1253). In patients with a high CNS international prognostic index (n = 600), the 3-year CNS relapse rate was 9.1%, with no difference between i-HD-MTX and EOT. On multivariable analysis, increasing age and renal/adrenal involvement were the only independent risk factors for CNS relapse. Concurrent intrathecal prophylaxis was not associated with a reduction in CNS relapse. R-CHOP delays of ≥7 days were significantly increased with i-HD-MTX vs EOT, with 308 of 1573 (19.6%) i-HD-MTX treatments resulting in a delay to subsequent R-CHOP (median 8 days). Increased risk of delay occurred in older patients when delivery was later than day 10 in the R-CHOP cycle. In summary, we found no evidence that EOT delivery increases CNS relapse risk vs i-HD-MTX. Findings in high-risk subgroups were unchanged. Rates of CNS relapse in this HD-MTX-treated cohort were similar to comparable cohorts receiving infrequent CNS prophylaxis. If HD-MTX is still considered for certain high-risk patients, delivery could be deferred until R-CHOP completion.

中文翻译:

DLBCL 中大剂量甲氨蝶呤 CNS 预防的时机:对 1384 名患者的多中心国际分析。

预防性大剂量甲氨蝶呤 (HD-MTX) 通常用于中枢神经系统 (CNS) 复发风险高的弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者,尽管证明疗效或最佳给药方法的证据有限。我们对 1384 名接受 HD-MTX 中枢神经系统预防的患者进行了一项回顾性国际分析,无论是插入 (i-HD-MTX) (n = 749) 还是在 R-CHOP/R-CHOP 样治疗结束时 (n = 635) (EOT)。有 78 例 CNS 复发(3 年复发率为 5.7%),i-HD-MTX 和 EOT 之间没有差异:5.7% vs 5.8%,P = .98;3 年差异:0.04%(-2.0% 至 3.1%)。调整基线预后因素或 6 个月标志性分析 (n = 1253) 得出的结论没有变化。在具有高 CNS 国际预后指数的患者(n = 600)中,3 年 CNS 复发率为 9.1%,i-HD-MTX 和 EOT 没有区别。在多变量分析中,年龄增加和肾脏/肾上腺受累是 CNS 复发的唯一独立危险因素。同时进行的鞘内预防与 CNS 复发的减少无关。i-HD-MTX 与 EOT 相比,R-CHOP 延迟≥7 天显着增加,1573 次 i-HD-MTX 治疗中有 308 次(19.6%)导致后续 R-CHOP 延迟(中位数 8 天)。当分娩晚于 R-CHOP 周期的第 10 天时,老年患者的延迟风险增加。总之,与 i-HD-MTX 相比,我们没有发现 EOT 给药增加 CNS 复发风险的证据。高风险亚组的结果没有变化。在这个 HD-MTX 治疗的队列中,CNS 复发率与接受不频繁 CNS 预防的可比队列相似。
更新日期:2022-01-07
down
wechat
bug